Trial Profile
Efficacy of novel cephalosporin/beta-lactamase inhibitors combination (avibactam/ceftazidime and ceftolozane/tazobactam for treatment of multidrug resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae in patient with solid organ transplant: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Ceftolozane/tazobactam (Primary)
- Indications Enterobacteriaceae infections; Pseudomonal infections
- Focus Therapeutic Use
- 11 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress